A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder
A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder
复制标题
DOI：
10.1016/j.jpsychires.2012.05.006
复制
发表时间：
2012-09-01
影响因子：
4.8
通讯作者：
Hofmann, Stefan G.
中科院分区：
文献类型：
--
作者：
Litz, Brett T.;Salters-Pedneault, Kristalyn;Hofmann, Stefan G.
D-环丝氨酸 (DCS) 是一种部分 NMDA 受体激动剂，已被证明可以增强对基于暴露的焦虑症治疗的治疗反应，但尚未在与战斗相关的创伤后应激障碍 (PTSD) 的治疗中进行测试。这项随机、双盲、安慰剂对照试验的目的是确定 DCS 是否能增强从伊拉克和阿富汗返回的退伍军人的 PTSD 暴露疗法，并测试短暂的六疗程暴露疗法是否可以有效减轻返回退伍军人的 PTSD 症状。与之前使用 DCS 增强暴露疗法的试验相比，结果表明，在治疗过程中，接受暴露疗法加 DCS 条件的退伍军人的症状减轻程度明显低于接受暴露疗法加安慰剂条件的退伍军人。讨论了 DCS 与较差结果相关的可能原因。
D-Cycloserine (DCS) is a partial NMDA receptor agonist that has been shown to enhance therapeutic response to exposure-based treatments for anxiety disorders, but has not been tested in the treatment of combat-related posttraumatic stress disorder (PTSD). The aim of this randomized, double-blind, placebo-controlled trial was to determine whether DCS augments exposure therapy for PTSD in veterans returning from Iraq and Afghanistan and to test whether a brief six-session course of exposure therapy could effectively reduce PTSD symptoms in returning veterans. In contrast to previous trials using DCS to enhance exposure therapy, results indicated that veterans in the exposure therapy plus DCS condition experienced significantly less symptom reduction than those in the exposure therapy plus placebo condition over the course of the treatment. Possible reasons for why DCS was associated with poorer outcome are discussed.